WHO Report Shows Increase in HIV Drug Resistance to Dolutegravir
10 March 2024
The World Health Organization’s HIV Drug Resistance Report reveals growing drug resistance in populations receiving dolutegravir-containing antiretroviral therapy (ART). However, levels of HIVDR to DTG are exceeding clinical trials. The report recommends dolutegravir as the preferred treatment due to its effectiveness, ease of use, and genetic barrier to resistance. Resistance to dolutegravir ranges from 3.9% to 8.6%, reaching 19.6% among those with high viral loads.
Further reading: Pharmaceutical Manufacturer
Author(s): Pharmaceutical Manufacturer
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!